Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

LYELLyell Immunopharma, Inc.

Nasdaq · CIK 0001806952
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts252

Identity from submissions API

NameLyell Immunopharma, Inc.
CIK0001806952
TickersLYEL
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN833006753
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone650 695-0677
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
201 HASKINS WAY
SOUTH SAN FRANCISCO
CA
94080
CA
Mailing address
201 HASKINS WAY
SOUTH SAN FRANCISCO
CA
94080
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

365 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-13 S-3 S-3 0001193125-26-460585 333-300032 261552306 33 359752 1 1
2026-11-12 4 xslF345X06/form4-11122026_091132.xml 0001907345-26-000008 4906
2026-11-12 4 xslF345X06/form4-11122026_091105.xml 0001866154-26-000008 4928
2026-11-12 4 xslF345X06/form4-11122026_091139.xml 0001327111-26-000008 4870
2026-11-12 4 xslF345X06/form4-11122026_091120.xml 0002095702-26-000007 4950
2026-11-10 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001012975-26-001025 005-93402 261541904 34 28686
2026-11-05 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001012975-26-001014 16947
2026-11-05 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001012975-26-001013 22317
2026-11-04 10-Q 10-Q 0001628280-26-070171 001-40502 261522542 34 11788210 1 1
2026-11-04 8-K 8-K 2.02,9.01 0001628280-26-070161 001-40502 261522398 34 319812 1 1
2026-11-04 8-K 8-K 3.02 0001193125-26-446317 001-40502 261520315 34 136429 1 1
2026-10-13 4 xslF345X06/form4-10132026_091052.xml 0002150331-26-000003 5382
2026-09-10 4 xslF345X06/form4-09102026_110937.xml 0001959742-26-000003 5337
2026-09-10 4 xslF345X06/form4-09102026_110951.xml 0002150331-26-000002 6819
2026-09-10 3 xslF345X06/form3-09102026_110902.xml 0002150331-26-000001 14901
2026-09-10 8-K 8-K 8.01,9.01 0001193125-26-387890 001-40502 261371241 34 161183 1 1
2026-08-25 4 xslF345X06/form4-08252026_080833.xml 0001327111-26-000006 4871
2026-08-25 4 xslF345X06/form4-08252026_080813.xml 0001866154-26-000006 4929
2026-08-25 4 xslF345X06/form4-08252026_080815.xml 0001907345-26-000006 4907
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-097073 005-93402 261281050 34 21429
2026-08-11 4 xslF345X06/form4-08112026_080848.xml 0002095702-26-000005 5399
2026-08-11 4 xslF345X06/form4-08112026_080834.xml 0001907345-26-000004 5355
2026-08-11 4 xslF345X06/form4-08112026_080811.xml 0001866154-26-000004 5377
2026-08-11 4 xslF345X06/form4-08112026_080842.xml 0001327111-26-000004 5319
2026-08-06 10-Q 10-Q 0001628280-26-054367 001-40502 261249572 34 11361534 1 1
2026-08-06 8-K 8-K 2.02,9.01 0001628280-26-054330 001-40502 261249240 34 321846 1 1
2026-07-27 4 FORM 4 0001140361-26-029817 5560
2026-07-27 4 FORM 4 0001140361-26-029791 5568
2026-07-21 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-002375 333-297433 261191571 33 1724
2026-07-20 4 FORM 4 0001140361-26-028955 5150
2026-07-17 4 FORM 4 0001140361-26-028846 5151
2026-07-17 CORRESP filename1.htm 0001193125-26-307470 7034
2026-07-16 UPLOAD filename1.pdf 0000000000-26-007086 333-297433 147280
2026-07-13 S-3 S-3 0001193125-26-302132 333-297433 261172000 33 353605 1 1
2026-07-01 4 FORM 4 0001140361-26-027140 5535
2026-06-18 4 xslF345X06/form4.xml 0001140361-26-025796 5529
2026-06-18 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001140361-26-025769 005-93402 261103256 34 9594
2026-06-18 3 FORM 3 0001140361-26-025740 4813
2026-06-15 4 xslF345X06/form4-06152026_100612.xml 0001327111-26-000003 5319
2026-06-15 4 xslF345X06/form4-06152026_100619.xml 0001907345-26-000003 5535
2026-06-15 4 xslF345X06/form4-06152026_100659.xml 0001866154-26-000003 5555
2026-06-15 4 xslF345X06/form4-06152026_100616.xml 0002095702-26-000004 5399
2026-06-15 8-K 8-K 5.07 0001193125-26-271071 001-40502 261090790 34 147606 1 1
2026-06-12 4 xslF345X06/form4-06122026_080603.xml 0001182471-26-000002 5897
2026-06-12 4 xslF345X06/form4-06122026_080637.xml 0001439368-26-000002 7021
2026-06-12 4 xslF345X06/form4-06122026_080608.xml 0001619929-26-000004 5864
2026-06-12 4 xslF345X06/form4-06122026_080656.xml 0001591178-26-000002 8357
2026-06-12 4 xslF345X06/form4-06122026_080616.xml 0001411874-26-000002 8542
2026-06-12 4 xslF345X06/form4-06122026_080623.xml 0001213029-26-000007 6760
2026-06-12 4 xslF345X06/form4-06122026_080602.xml 0001887762-26-000002 5891
2026-06-11 4 xslF345X06/form4-06112026_080646.xml 0001959742-26-000002 5069
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001012975-26-000439 005-93402 26986937 34 27948
2026-05-11 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-216076 005-93402 26961539 34 9115
2026-05-08 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001168404-26-000021 005-93402 26958750 34 10992
2026-05-06 10-Q 10-Q 0001628280-26-031284 001-40502 26948597 34 10459969 1 1
2026-05-06 8-K 8-K 2.02,9.01 0001628280-26-031269 001-40502 26948457 34 291048 1 1
2026-04-24 ARS ARS 0001140361-26-016690 001-40502 26893706 34 4158610
2026-04-24 DEFA14A DEFA14A 0001140361-26-016688 001-40502 26893684 34 1211663
2026-04-24 DEF 14A DEF 14A 0001140361-26-016686 001-40502 26893581 34 5003477 1 1
2026-04-21 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-165277 005-93402 26876884 34 11403
2026-04-14 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001185 333-294884 26862414 33 1723
2026-04-13 CORRESP filename1.htm 0001193125-26-151895 7083
2026-04-08 UPLOAD filename1.pdf 0000000000-26-003547 333-294884 40023
2026-04-03 S-3 S-3 0001193125-26-142213 333-294884 26838419 33 324312 1 1
2026-03-16 4 xslF345X05/form4-03162026_110321.xml 0001808821-26-000006 5498
2026-03-16 3 xslF345X02/form3-03162026_110346.xml 0001808821-26-000005 9289
2026-03-12 S-8 S-8 0001193125-26-104336 333-294257 26748607 33 202666 1 1
2026-03-12 10-K 10-K 0001628280-26-017253 001-40502 26747964 34 18792604 1 1
2026-03-12 8-K 8-K 2.02,9.01 0001628280-26-017244 001-40502 26747834 34 291398 1 1
2026-03-09 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001012975-26-000235 16418
2026-03-09 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001012975-26-000234 21440
2026-03-09 8-K 8-K 5.02,9.01 0001193125-26-097615 001-40502 26733257 34 200857 1 1
2026-02-12 4 xslF345X05/form4-02132026_010246.xml 0001327111-26-000002 5204
2026-02-12 4 xslF345X05/form4-02132026_010228.xml 0001866154-26-000002 5263
2026-02-12 4 xslF345X05/form4-02132026_010253.xml 0001907345-26-000002 5240
2026-02-11 4 xslF345X05/form4-02122026_020218.xml 0001866154-26-000001 9686
2026-02-11 4 xslF345X05/form4-02122026_020216.xml 0001907345-26-000001 9663
2026-02-11 4 xslF345X05/form4-02122026_020200.xml 0001327111-26-000001 9450
2026-02-11 4 xslF345X05/form4-02122026_020247.xml 0001771329-26-000001 5962
2026-02-11 4 xslF345X05/form4-02122026_020223.xml 0002095702-26-000002 6731
2026-02-11 4 xslF345X05/form4-02122026_010247.xml 0001959742-26-000001 6622
2026-01-06 4 xslF345X05/form4-01062026_090153.xml 0002095702-26-000001 6544
2025-12-18 424B5 424B5 0001193125-25-324801 333-291970 251583063 33 243337
2025-12-15 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-003741 333-291970 251573263 33 1724
2025-12-11 CORRESP filename1.htm 0001193125-25-315941 7227
2025-12-08 8-K 8-K 8.01 0001193125-25-310469 001-40502 251554515 34 145452 1 1
2025-12-05 S-3 S-3 0001193125-25-309779 333-291970 251553486 33 581920 1 1
2025-12-05 8-K 8-K 5.03,9.01 0001193125-25-309621 001-40502 251552944 34 373493 1 1
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001012975-25-000768 005-93402 251487015 34 65627
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-112479 005-93402 251485824 34 22825
2025-11-13 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001140361-25-042006 005-93402 251479627 34 6761
2025-11-12 4 xslF345X05/form4-11132025_011139.xml 0001327111-25-000007 4733
2025-11-12 4 xslF345X05/form4-11132025_011155.xml 0002095702-25-000003 5261
2025-11-12 4 xslF345X05/form4-11132025_011126.xml 0001907345-25-000006 4751
2025-11-12 4 xslF345X05/form4-11132025_011153.xml 0001866154-25-000006 4791
2025-11-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-25-277861 005-93402 251473919 34 10941
2025-11-12 10-Q 10-Q 0001628280-25-051619 001-40502 251473098 34 10845034 1 1
2025-11-12 8-K 8-K 2.02,9.01 0001628280-25-051603 001-40502 251472846 34 294015 1 1
2025-11-10 3 xslF345X02/form3-11112025_021155.xml 0002095702-25-000002 14567
2025-11-10 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-25-273269 001-40502 251464357 34 178312 1 1
2025-11-03 8-K 8-K 5.02 0001193125-25-261753 001-40502 251442227 34 134520 1 1
2025-10-29 4 xslF345X05/form4-10292025_091048.xml 0001866154-25-000005 12265
2025-10-29 4 xslF345X05/form4-10292025_091031.xml 0001907345-25-000005 12248
2025-10-29 4 xslF345X05/form4-10292025_091010.xml 0001327111-25-000006 12205
2025-09-16 8-K 8-K 5.02 0001193125-25-205020 001-40502 251317580 34 132779 1 1
2025-08-22 4 xslF345X05/form4-08222025_080818.xml 0001415889-25-022747 7169
2025-08-22 4 xslF345X05/form4-08222025_080857.xml 0001415889-25-022746 7225
2025-08-22 4 xslF345X05/form4-08222025_080821.xml 0001415889-25-022741 8082
2025-08-22 4 xslF345X05/form4-08222025_080803.xml 0001415889-25-022740 7202
2025-08-19 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-022288 005-93402 251231882 34 15440
2025-08-15 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002652 333-289539 251226170 33 1724
2025-08-13 4 xslF345X05/form4-08142025_010843.xml 0001415889-25-021694 7778
2025-08-13 4 xslF345X05/form4-08142025_010830.xml 0001415889-25-021693 8011
2025-08-13 4 xslF345X05/form4-08142025_010810.xml 0001415889-25-021692 7990
2025-08-13 4 xslF345X05/form4-08142025_010858.xml 0001415889-25-021691 8888
2025-08-13 CORRESP filename1.htm 0001193125-25-179830 7077
2025-08-13 UPLOAD filename1.pdf 0000000000-25-008503 333-289539 40037
2025-08-12 S-3 S-3 0001193125-25-179042 333-289539 251207539 33 340850 1 1
2025-08-12 10-Q 10-Q 0001806952-25-000008 001-40502 251206848 34 10124159 1 1
2025-08-12 8-K 8-K 2.02,9.01 0001806952-25-000007 001-40502 251206777 34 286077 1 1
2025-08-01 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-073122 005-93402 251176374 34 17199
2025-07-31 424B5 424B5 0001193125-25-170528 333-288769 251171798 33 457346
2025-07-30 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-002413 333-288769 251169104 33 1724
2025-07-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-013262 18443
2025-07-29 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-013261 15997
2025-07-28 CORRESP filename1.htm 0001193125-25-166426 6781
2025-07-25 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-25-164853 001-40502 251148637 34 523668 1 1
2025-07-23 UPLOAD filename1.pdf 0000000000-25-007760 333-288769 40063
2025-07-18 S-3 S-3 0001193125-25-161227 333-288769 251134739 33 721647 1 1
2025-06-26 8-K 8-K 3.02 0001193125-25-148897 001-40502 251080418 34 134564 1 1
2025-06-17 8-K 8-K 8.01 0001193125-25-141795 001-40502 251052004 34 147570 1 1
2025-06-11 4 xslF345X05/form4-06112025_090624.xml 0001415889-25-016730 5603
2025-06-11 4 xslF345X05/form4-06112025_090608.xml 0001415889-25-016729 5533
2025-06-11 4 xslF345X05/form4-06112025_090645.xml 0001415889-25-016728 7402
2025-06-11 3 xslF345X02/form3-06112025_090624.xml 0001415889-25-016727 9285
2025-06-11 3 xslF345X02/form3-06112025_090646.xml 0001415889-25-016726 9283
2025-06-11 3 xslF345X02/form3-06112025_090654.xml 0001415889-25-016725 9272
2025-06-09 8-K 8-K 5.02 0001193125-25-137853 001-40502 251034420 34 134235 1 1
2025-05-28 8-K 8-K 3.03,9.01 0001193125-25-129448 001-40502 25995293 34 150854 1 1
2025-05-21 8-K 8-K 5.07 0001193125-25-123970 001-40502 25973124 34 147792 1 1
2025-05-19 4 xslF345X05/form4-05192025_100514.xml 0001415889-25-013723 7957
2025-05-19 4 xslF345X05/form4-05192025_100545.xml 0001415889-25-013719 5771
2025-05-19 4 xslF345X05/form4-05192025_100556.xml 0001415889-25-013712 8134
2025-05-19 4 xslF345X05/form4-05192025_100517.xml 0001415889-25-013710 6395
2025-05-19 4 xslF345X05/form4-05192025_100536.xml 0001415889-25-013707 5738
2025-05-19 4 xslF345X05/form4-05192025_100544.xml 0001415889-25-013705 6657
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-049403 005-93402 25952592 34 22943
2025-05-13 10-Q 10-Q 0001628280-25-025135 001-40502 25940862 34 12180846 1 1
2025-05-13 8-K 8-K 2.02,9.01 0001628280-25-025128 001-40502 25940841 34 268710 1 1
2025-04-21 ARS ARS 0001140361-25-014722 001-40502 25853189 34 5446695
2025-04-21 DEF 14A DEF 14A 0001140361-25-014721 001-40502 25853171 34 5610937 1 1
2025-04-10 PRE 14A PRE 14A 0001140361-25-013293 001-40502 25829072 34 5595263 1 1
2025-04-02 4 xslF345X05/form4-04022025_070458.xml 0001415889-25-009604 4528
2025-04-01 8-K 8-K 2.05,5.02,7.01 0001193125-25-070521 001-40502 25800668 34 151227 1 1
2025-03-25 4 xslF345X05/form4-03252025_100313.xml 0001415889-25-008942 5347
2025-03-18 4 xslF345X05/form4-03192025_120347.xml 0001415889-25-008540 6650
2025-03-18 4 xslF345X05/form4-03182025_110331.xml 0001415889-25-008517 6037
2025-03-18 4 xslF345X05/form4-03182025_100315.xml 0001415889-25-008509 5108
2025-03-11 S-8 S-8 0001193125-25-051999 333-285717 25728366 33 79000
2025-03-11 10-K 10-K 0001628280-25-011978 001-40502 25727736 34 16197247 1 1
2025-03-11 8-K 8-K 2.02,9.01 0001628280-25-011960 001-40502 25727605 34 306087 1 1
2025-02-26 4 xslF345X05/form4-02272025_120200.xml 0001415889-25-005775 9672
2025-02-26 4 xslF345X05/form4-02272025_120243.xml 0001415889-25-005768 9656
2025-02-26 4 xslF345X05/form4-02272025_120219.xml 0001415889-25-005760 9937
2025-02-26 4 xslF345X05/form4-02272025_120230.xml 0001415889-25-005753 9873
2025-02-26 4 xslF345X05/form4-02272025_120251.xml 0001415889-25-005747 9913
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001072613-25-000168 005-93402 25630386 34 35397
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-013912 005-93402 25626729 34 23118
2025-02-05 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-001224 005-93402 25592232 34 11764
2025-01-24 8-K 8-K 3.01 0001193125-25-012249 001-40502 25554681 34 146797 1 1
2025-01-10 8-K/A 8-K/A 9.01 0001628280-25-001065 001-40502 25520734 34 1424813 1 1
2024-12-10 8-K 8-K 8.01,9.01 0001193125-24-273688 001-40502 241536881 34 169851 1 1
2024-12-09 424B5 424B5 0001193125-24-272943 333-283533 241533958 33 548686
2024-12-05 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-12-05 16:00:00 9999999995-24-003682 333-283533 241530412 33 1731
2024-12-03 CORRESP filename1.htm 0001193125-24-269995 6839
2024-12-03 UPLOAD filename1.pdf 0000000000-24-013301 333-283533 40116
2024-11-29 S-3 S-3 0001193125-24-268106 333-283533 241516560 33 815354 1 1
2024-11-26 8-K 8-K 5.02 0001193125-24-266101 001-40502 241503675 34 140117 1 1
2024-11-12 SC 13G/A UnitedStates_13G__LyellImmun.txt 0000932471-24-001105 005-93402 241447889 34 6525
2024-11-07 10-Q 10-Q 0001628280-24-046285 001-40502 241435996 34 7960593 1 1
2024-11-07 8-K 8-K 2.02,9.01 0001628280-24-046254 001-40502 241435687 34 285273 1 1
2024-11-04 SC 13G/A UnitedStates_13G__LyellImmun.txt 0000932471-24-000620 005-93402 241422218 34 5581
2024-11-01 4 xslF345X05/form4-11012024_081136.xml 0001415889-24-025912 5583
2024-11-01 3 xslF345X02/form3-11012024_081129.xml 0001415889-24-025909 9071
2024-10-31 SC 13G SC 13G 0001104659-24-113135 005-93402 241416467 34 134104
2024-10-31 8-K 8-K 1.01,2.01,5.02,7.01,9.01 0001193125-24-248760 001-40502 241415848 34 328822 1 1
2024-10-24 8-K 8-K 1.01,3.02,7.01,8.01,9.01 0001193125-24-242808 001-40502 241392663 34 1007113 1 1
2024-08-07 10-Q 10-Q 0001628280-24-035617 001-40502 241183765 34 7386383 1 1
2024-08-07 8-K 8-K 2.02,9.01 0001628280-24-035603 001-40502 241183649 34 290655 1 1
2024-06-26 8-K 8-K 7.01,8.01,9.01 0001193125-24-168597 001-40502 241070704 34 15782685 1 1
2024-06-17 4 xslF345X05/form4-06172024_080644.xml 0001415889-24-017220 14921
2024-06-17 4 xslF345X05/form4-06172024_080643.xml 0001415889-24-017183 12540
2024-06-17 4 xslF345X05/form4-06172024_080654.xml 0001415889-24-017176 14574
2024-06-17 4 xslF345X05/form4-06172024_080620.xml 0001415889-24-017162 11914
2024-06-17 4 xslF345X05/form4-06172024_080605.xml 0001415889-24-017152 11896
2024-06-17 4 xslF345X05/form4-06172024_080619.xml 0001415889-24-017147 11859
2024-06-17 4 xslF345X05/form4-06172024_080617.xml 0001415889-24-017146 14280
2024-06-14 8-K 8-K 5.07 0001193125-24-161601 001-40502 241044768 34 153302 1 1
2024-05-06 424B5 424B5 0001193125-24-131492 333-277495 24915654 33 495263
2024-05-06 10-Q 10-Q 0001628280-24-020467 001-40502 24915647 34 6554073 1 1
2024-05-06 8-K 8-K 2.02,9.01 0001628280-24-020466 001-40502 24915638 34 257075 1 1
2024-05-03 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-05-03 16:30:00 9999999995-24-001369 333-277495 24915364 33 1730
2024-05-01 CORRESP filename1.htm 0001193125-24-127548 7313
2024-04-22 ARS ARS 0001140361-24-021014 001-40502 24861400 34 2964761
2024-04-22 DEFA14A DEFA14A 0001140361-24-021011 001-40502 24861387 34 1220414
2024-04-22 DEF 14A DEF 14A 0001140361-24-021008 001-40502 24861371 34 5631876 1 1
2024-03-04 UPLOAD filename1.pdf 0000000000-24-002403 333-277495 40270
2024-02-29 S-3 S-3 0001193125-24-051177 333-277495 24698182 33 1426104
2024-02-29 S-8 S-8 0001193125-24-051169 333-277494 24698155 33 84640
2024-02-28 10-K 10-K 0001628280-24-007592 001-40502 24695507 34 14201141 1 1
2024-02-28 8-K 8-K 2.02,9.01 0001628280-24-007579 001-40502 24695285 34 299261 1 1
2024-02-14 SC 13G/A ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA -- SCH 13G/A(#1) 0001072613-24-000252 005-93402 24636717 34 277144
2024-02-13 4 FORM 4 SUBMISSION 0001209191-24-003276 7425
2024-02-13 4 FORM 4 SUBMISSION 0001209191-24-003274 11107
2024-02-13 4 FORM 4 SUBMISSION 0001209191-24-003272 11083
2024-02-13 4 FORM 4 SUBMISSION 0001209191-24-003270 11030
2024-02-13 4 FORM 4 SUBMISSION 0001209191-24-003269 4991
2024-02-13 SC 13G/A SCHEDULE 13G/A 0001104659-24-021383 005-93402 24628870 34 13026
2024-01-29 SC 13G us55083r1041_012924.txt 0001086364-24-005606 005-93402 24574940 34 13556
2023-11-20 4 FORM 4 SUBMISSION 0001209191-23-056181 24351
2023-11-20 4 FORM 4 SUBMISSION 0001209191-23-056180 9995
2023-11-20 4 FORM 4 SUBMISSION 0001209191-23-056179 9030
2023-11-20 4 FORM 4 SUBMISSION 0001209191-23-056178 33842
2023-11-20 8-K 8-K 5.02 0001193125-23-280680 001-40502 231423107 34 144689 1 1
2023-11-07 10-Q 10-Q 0001628280-23-037360 001-40502 231384092 34 8538263 1 1
2023-11-07 8-K 8-K 2.02,9.01 0001628280-23-037346 001-40502 231383748 34 292827 1 1
2023-09-11 8-K 8-K 7.01,9.01 0001193125-23-232064 001-40502 231246956 34 13719461 1 1
2023-09-08 4 FORM 4 SUBMISSION 0001209191-23-048788 8017
2023-09-08 4 FORM 4 SUBMISSION 0001209191-23-048786 6201
2023-09-08 4 FORM 4 SUBMISSION 0001209191-23-048785 8675
2023-09-08 4 FORM 4 SUBMISSION 0001209191-23-048784 9273
2023-09-08 4 FORM 4 SUBMISSION 0001209191-23-048783 6178
2023-09-08 4 FORM 4 SUBMISSION 0001209191-23-048782 6144
2023-09-08 4 FORM 4 SUBMISSION 0001209191-23-048779 6771
2023-08-17 4 FORM 4 SUBMISSION 0001209191-23-046267 6293
2023-08-15 144 xsl144X01/primary_doc.xml 0001974078-23-000125 001-40502 231174602 33 4163
2023-08-15 144 xsl144X01/primary_doc.xml 0001974078-23-000124 001-40502 231174590 33 4163
2023-08-15 144 xsl144X01/primary_doc.xml 0001974078-23-000123 001-40502 231174563 33 4165
2023-08-15 144 xsl144X01/primary_doc.xml 0001974078-23-000122 001-40502 231174553 33 4163
2023-08-11 4 FORM 4 SUBMISSION 0001209191-23-045439 5389
2023-08-08 10-Q 10-Q 0001628280-23-028215 001-40502 231151734 34 7201258 1 1
2023-08-08 8-K 8-K 2.02,9.01 0001628280-23-028189 001-40502 231151383 34 291813 1 1
2023-07-20 3 FORM 3 SUBMISSION 0001209191-23-042866 6295
2023-07-17 144 xsl144X01/primary_doc.xml 0001974078-23-000092 001-40502 231092523 33 4225
2023-07-17 144 xsl144X01/primary_doc.xml 0001974078-23-000091 001-40502 231092519 33 4223
2023-07-17 144 xsl144X01/primary_doc.xml 0001974078-23-000090 001-40502 231092506 33 4223
2023-07-17 144 xsl144X01/primary_doc.xml 0001974078-23-000089 001-40502 231092497 33 4223
2023-06-21 8-K 8-K 5.07 0001193125-23-171240 001-40502 231030581 34 160236 1 1
2023-06-20 4 FORM 4 SUBMISSION 0001209191-23-038449 5691
2023-06-20 4 FORM 4 SUBMISSION 0001209191-23-038445 8762
2023-06-20 4 FORM 4 SUBMISSION 0001209191-23-038441 5667
2023-06-20 4 FORM 4 SUBMISSION 0001209191-23-038439 7510
2023-06-20 4 FORM 4 SUBMISSION 0001209191-23-038437 8165
2023-06-20 4 FORM 4 SUBMISSION 0001209191-23-038435 5633
2023-06-20 4 FORM 4 SUBMISSION 0001209191-23-038433 6261
2023-06-06 8-K 8-K 5.02 0001193125-23-161594 001-40502 23996049 34 144211 1 1
2023-05-04 10-Q 10-Q 0001628280-23-015765 001-40502 23889072 34 6695877 1 1
2023-05-04 8-K 8-K 2.02,9.01 0001628280-23-015733 001-40502 23888819 34 278322 1 1
2023-04-28 ARS ARS 0001140361-23-021541 001-40502 23866239 34 2093360
2023-04-27 DEFA14A FORM DEFA14A 0001140361-23-020926 001-40502 23856875 34 1072219
2023-04-27 DEF 14A DEF 14A 0001140361-23-020919 001-40502 23856836 34 5466167 1 1
2023-02-28 4 FORM 4 SUBMISSION 0001209191-23-013850 6182
2023-02-28 4 FORM 4 SUBMISSION 0001209191-23-013848 6225
2023-02-28 4 FORM 4 SUBMISSION 0001209191-23-013844 6159
2023-02-28 4 FORM 4 SUBMISSION 0001209191-23-013839 5356
2023-02-28 4 FORM 4 SUBMISSION 0001209191-23-013836 6115
2023-02-28 S-8 S-8 0001193125-23-054284 333-270145 23687630 33 79737
2023-02-28 10-K 10-K 0001628280-23-005572 001-40502 23685778 34 12923536 1 1
2023-02-28 8-K 8-K 2.02,9.01 0001628280-23-005554 001-40502 23685377 34 312345 1 1
2023-02-13 SC 13G/A SC 13G/A 0001104659-23-019827 005-93402 23619644 34 78846
2023-02-09 SC 13G SCHEDULE 13G 0001104659-23-016396 005-93402 23603626 34 12915
2022-12-19 4 FORM 4 SUBMISSION 0001209191-22-061898 5498
2022-12-16 8-K 8-K 5.02,9.01 0001193125-22-307296 001-40502 221467886 34 299393 1 1
2022-11-08 10-Q 10-Q 0001628280-22-028929 001-40502 221369154 34 8966933 1 1
2022-11-08 8-K 8-K 2.02,9.01 0001628280-22-028908 001-40502 221368919 34 305975 1 1
2022-10-24 8-K 8-K 1.02 0001628280-22-026904 001-40502 221326590 34 183487 1 1
2022-10-12 4 FORM 4 SUBMISSION 0001209191-22-053457 5360
2022-10-06 8-K 8-K 7.01,9.01 0001193125-22-258907 001-40502 221298511 34 175031 1 1
2022-10-03 3 FORM 3 SUBMISSION 0001209191-22-051817 6258
2022-09-27 4 FORM 4 SUBMISSION 0001209191-22-051379 5688
2022-09-09 4 FORM 4 SUBMISSION 0001209191-22-049299 6991
2022-08-04 S-3ASR S-3ASR 0001193125-22-212689 333-266548 221137877 33 1405369
2022-08-04 10-Q 10-Q 0001628280-22-021109 001-40502 221137244 34 9020452 1 1
2022-08-04 8-K 8-K 2.02,9.01 0001628280-22-021080 001-40502 221136778 34 298926 1 1
2022-06-13 8-K 8-K 5.07 0001193125-22-172997 001-40502 221012293 34 152029 1 1
2022-06-10 4 FORM 4 SUBMISSION 0001209191-22-035879 5657
2022-06-10 4 FORM 4 SUBMISSION 0001209191-22-035872 8728
2022-06-10 4 FORM 4 SUBMISSION 0001209191-22-035866 5608
2022-06-10 4 FORM 4 SUBMISSION 0001209191-22-035858 5633
2022-06-10 4 FORM 4 SUBMISSION 0001209191-22-035853 5599
2022-06-10 4 FORM 4 SUBMISSION 0001209191-22-035846 6227
2022-06-10 4 FORM 4 SUBMISSION 0001209191-22-035837 8131
2022-06-10 4 FORM 4 SUBMISSION 0001209191-22-035825 7338
2022-05-10 10-Q 10-Q 0001628280-22-013611 001-40502 22910202 34 8226412 1 1
2022-05-10 8-K 8-K 2.02,9.01 0001628280-22-013590 001-40502 22909765 34 274802 1 1
2022-04-28 DEF 14A DEF 14A 0001140361-22-016525 001-40502 22866657 34 2188954
2022-03-29 3 FORM 3 SUBMISSION 0001209191-22-021496 9934
2022-03-29 S-8 S-8 0001193125-22-088224 333-263952 22781702 33 85992
2022-03-29 10-K 10-K 0001628280-22-007708 001-40502 22781108 34 17754606 1 1
2022-03-29 8-K 8-K 2.02,9.01 0001628280-22-007701 001-40502 22780940 34 317289 1 1
2022-03-18 4 FORM 4 SUBMISSION 0001209191-22-020008 5324
2022-03-18 4 FORM 4 SUBMISSION 0001209191-22-020006 5399
2022-03-18 4 FORM 4 SUBMISSION 0001209191-22-020004 5400
2022-03-18 4 FORM 4 SUBMISSION 0001209191-22-020001 5400
2022-02-25 4 FORM 4 SUBMISSION 0001209191-22-013118 6991
2022-02-15 8-K 8-K 5.02 0001193125-22-043467 001-40502 22639832 34 158319 1 1
2022-02-14 4 FORM 4 SUBMISSION 0001209191-22-009580 5373
2022-02-14 SC 13G SC 13G 0001193125-22-041763 005-93402 22632270 34 49023
2022-02-14 SC 13G SC 13G 0001193125-22-041692 005-93402 22631859 34 79703
2022-02-14 SC 13G ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA -- SCH 13G 0001072613-22-000148 005-93402 22627825 34 270276
2022-02-11 SC 13G SC 13G 0001104659-22-020368 005-93402 22619981 34 71182
2022-02-10 SC 13G SCHEDULE 13G 0001387131-22-001554 005-93402 22614900 34 26587
2022-02-04 3 FORM 3 SUBMISSION 0001209191-22-007155 6353
2021-12-17 8-K 8-K 1.01,8.01,9.01 0001193125-21-361060 001-40502 211501444 34 203979 1 1
2021-12-14 4 FORM 4 SUBMISSION 0001209191-21-069485 8134
2021-12-03 8-K 8-K 8.01 0001193125-21-346888 001-40502 211467989 34 143448 1 1
2021-11-12 10-Q 10-Q 0000950170-21-004270 001-40502 211399931 34 10081106 1 1
2021-11-12 8-K 8-K 2.02,9.01 0000950170-21-004264 001-40502 211399866 34 620429 1 1
2021-10-28 8-K 8-K 5.02 0001193125-21-309692 001-40502 211354534 34 146697 1 1
2021-10-01 8-K/A 8-K/A 5.02 0001193125-21-288697 001-40502 211296957 34 150559 1 1
2021-09-30 8-K 8-K 5.02,9.01 0001193125-21-287960 001-40502 211295136 34 155091 1 1
2021-09-14 4 FORM 4 SUBMISSION 0001209191-21-055899 5341
2021-08-12 10-Q 10-Q 0000950170-21-001389 001-40502 211168586 34 9201440 1 1
2021-08-12 8-K 8-K 2.02,9.01 0000950170-21-001370 001-40502 211167821 34 570901 1 1
2021-06-23 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001387131-21-006822 7839
2021-06-23 4 FORM 4 SUBMISSION 0000899243-21-025523 27004
2021-06-23 4 FORM 4 SUBMISSION 0001209191-21-042801 18018
2021-06-23 4 FORM 4 SUBMISSION 0001209191-21-042798 8218
2021-06-23 4 FORM 4 SUBMISSION 0001209191-21-042796 6896
2021-06-23 4 FORM 4 SUBMISSION 0001209191-21-042795 10967
2021-06-21 S-8 S-8 0001193125-21-195237 333-257249 211031743 33 543134
2021-06-21 424B4 424B4 0001193125-21-193519 333-256470 211026820 33 7179238
2021-06-17 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001387131-21-006635 5059
2021-06-16 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-06-16 16:00:00 9999999995-21-002371 333-256470 211023275 33 1738
2021-06-16 3 FORM 3 SUBMISSION 0000899243-21-024324 19332
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041113 9845
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041112 7613
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041111 7659
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041110 10296
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041108 13501
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041107 7641
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041104 12955
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041102 12530
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041100 12175
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041096 7609
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041094 9851
2021-06-16 3 FORM 3 SUBMISSION 0001209191-21-041093 12199
2021-06-16 SEC STAFF LETTER filename1.pdf 9999999997-21-003468 271684
2021-06-16 CERT 8A_Cert_LYEL.pdf 0001354457-21-000669 001-40502 211020837 34 310843
2021-06-14 8-A12B 8-A12B 0001193125-21-190157 001-40502 211015237 34 13461
2021-06-14 CORRESP filename1.htm 0001193125-21-190090 16132
2021-06-14 CORRESP filename1.htm 0001193125-21-190080 7947
2021-06-09 S-1/A S-1/A 0001193125-21-185918 333-256470 211003966 33 9071922
2021-06-07 CORRESP filename1.htm 0001193125-21-183938 17721
2021-06-04 UPLOAD filename1.pdf 0000000000-21-006981 43530
2021-06-01 CORRESP filename1.htm 0001193125-21-178234 23558
2021-05-28 CORRESP filename1.htm 0001193125-21-177261 129774
2021-05-28 SEC STAFF LETTER filename1.pdf 9999999997-21-003151 272665
2021-05-25 UPLOAD filename1.pdf 0000000000-21-006587 44150
2021-05-25 S-1 S-1 0001193125-21-172500 333-256470 21961832 33 15405242
2021-05-12 DRSLTR filename1.htm 0000950123-21-006100 44471
2021-05-12 DRS/A filename1.htm 0000950123-21-006098 377-04650 21916248 33 7190348
2021-05-07 UPLOAD filename1.pdf 0000000000-21-005899 55935
2021-04-12 DRS filename1.htm 0000950123-21-004496 377-04650 21821435 33 14825360
2020-03-20 D xslFormDX01/primary_doc.xml 06b 0001806952-20-000001 021-363351 20731123 33 14783

Latest XBRL company facts

One latest value per concept from companyfacts (252 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 24.59M 2026-10-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
dei EntityPublicFloat Entity Public Float USD 129.00M 2025-06-30 2025 FY 10-K 2026-03-12 0001628280-26-017253
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 3.60M 2025-01-01 2025-12-31 DEF 14A 2026-04-24 0001140361-26-016686
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 2.01M 2025-01-01 2025-12-31 DEF 14A 2026-04-24 0001140361-26-016686
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 9.64M 2025-01-01 2025-12-31 DEF 14A 2026-04-24 0001140361-26-016686
ecd PeoTotalCompAmt PeoTotalCompAmt USD 4.22M 2025-01-01 2025-12-31 DEF 14A 2026-04-24 0001140361-26-016686
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 44.35 2025-01-01 2025-12-31 DEF 14A 2026-04-24 0001140361-26-016686
ffd NetFeeAmt NetFeeAmt USD 9,965.01 2026-11-13 S-3 2026-11-13 0001193125-26-460585
ffd TtlFeeAmt TtlFeeAmt USD 9,965.01 2026-11-13 S-3 2026-11-13 0001193125-26-460585
ffd TtlOfferingAmt TtlOfferingAmt USD 114.54M 2026-11-13 S-3 2026-11-13 0001193125-26-460585
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-11-13 S-3 2026-11-13 0001193125-26-460585
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-11-13 S-3 2026-11-13 0001193125-26-460585
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 4.04M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 2.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 11.15M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 42.24M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 670,000 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 74.28M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -278,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 1.93B 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.49B 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 13.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 13.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 49.44M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0001628280-22-021109
us-gaap AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable USD 33.97M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap AssetAcquisitionContingentConsiderationLiability AssetAcquisitionContingentConsiderationLiability USD 7.60M 2024-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap AssetAcquisitionContingentConsiderationLiabilityCurrent AssetAcquisitionContingentConsiderationLiabilityCurrent USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap Assets Assets USD 273.85M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AssetsCurrent Assets, Current USD 186.21M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 177.88M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 278,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 178.15M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value USD 312.50M 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value USD 312.50M 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 177.88M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 79,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 92.05M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 93.64M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 31.87M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 500.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 24.58M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 24.58M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap CommonStockValue Common Stock, Value, Issued USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -114.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 0 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 0 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 194.47M 2021-06-17 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months USD 107.70M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 621.60M 2022-06-30 2022 Q2 10-Q 2022-08-04 0001628280-22-021109
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 5.23M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsCapitalLossCarryforwards Deferred Tax Assets, Capital Loss Carryforwards USD 14.59M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 936,000 2024-12-31 2024 FY 10-K 2025-03-11 0001628280-25-011978
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 30.11M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 434.18M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsInvestments Deferred Tax Assets, Investments USD 7.76M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 5.23M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 242.84M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 819,000 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 10.76M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 42.50M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 7.89M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 3.07M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 428.95M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 5.23M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 0 2024-12-31 2024 FY 10-K 2025-03-11 0001628280-25-011978
us-gaap DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer USD 1.20M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 800,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap Depreciation Depreciation USD 10.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 6.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap DividendsPreferredStock Dividends, Preferred Stock USD 1.14M 2019-01-01 2019-12-31 2021 FY 10-K 2022-03-29 0001628280-22-007708
us-gaap DueToRelatedPartiesCurrent Due to Related Parties, Current USD 0 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap DueToRelatedPartiesNoncurrent Due to Related Parties, Noncurrent USD 0 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -4.93 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -1.66 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -4.93 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.196 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0.008 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.021 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.046 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.013 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 33.20M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap EquitySecuritiesFvNi Equity Securities, FV-NI USD 1.07M 2021-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap EquitySecuritiesFvNiCurrentAndNoncurrent EquitySecuritiesFvNiCurrentAndNoncurrent USD 30,000 2024-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap EquitySecuritiesFvNiUnrealizedGain Equity Securities, FV-NI, Unrealized Gain USD 30,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0001628280-25-011978
us-gaap EquitySecuritiesFvNiUnrealizedGainLoss Equity Securities, FV-NI, Unrealized Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap EquitySecuritiesFvNiUnrealizedLoss Equity Securities, FV-NI, Unrealized Loss USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0001628280-25-011978
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value USD 0 2022-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap FinancialLiabilitiesFairValueDisclosure Financial Liabilities Fair Value Disclosure USD 227,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap GainLossOnDispositionOfAssets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property USD -117,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap GainLossOnSaleOfOtherInvestments Gain (Loss) on Sale of Other Investments USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0001628280-25-011978
us-gaap GainLossOnTerminationOfLease Gain (Loss) on Termination of Lease USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 28.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 5.00M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0001628280-22-028929
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap IncomeTaxExaminationPenaltiesAndInterestAccrued Income Tax Examination, Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 53.78M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -57.63M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD -2.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 5.83M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -14,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD -115,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 3.56M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 1.06M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 7.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0001628280-25-011978
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -7.70M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-11 0001628280-25-011978
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 30,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -3.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 6.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap InterestIncomeOther Interest Income, Other USD 842,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 52.19M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 2.33M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 13.34M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 9.86M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 9.86M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 10.40M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 13.01M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 3.26M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 7.91M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap Liabilities Liabilities USD 81.13M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 273.85M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap LiabilitiesCurrent Liabilities, Current USD 46.27M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 85.05M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 16.88M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 52.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 86.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -107.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -114.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -183.12M 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap NetRentableArea Net Rentable Area sqft 11,000 2021-05-31 2022 Q2 10-Q 2022-08-04 0001628280-22-021109
us-gaap NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 25.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap NumberOfOperatingSegments Number of Operating Segments segment 1 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap NumberOfReportableSegments Number of Reportable Segments segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingExpenses Operating Expenses USD 139.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -139.89M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingLeaseCost Operating Lease, Cost USD 6.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 44.28M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 9.97M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 34.31M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingLeasePayments Operating Lease, Payments USD 9.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 15.73M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.085 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 2.56M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 5.91M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -49,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -520,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -520,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OtherInvestments Other Investments USD 19.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 547,000 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -324,000 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-12 0000950170-21-001389
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 19.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap OtherOperatingIncomeExpenseNet Other Operating Income (Expense), Net USD 5.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap PaymentsForRepurchaseOfPreferredStockAndPreferenceStock Payments for Repurchase of Preferred Stock and Preference Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 33.20M 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 0 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-06 0001628280-26-031284
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 134.29M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PaymentsToAcquireOtherInvestments Payments to Acquire Other Investments USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 411,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PreferredStockDividendsIncomeStatementImpact Preferred Stock Dividends, Income Statement Impact USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 9.11M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 50.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 221.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 5,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 67,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 522,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 109.05M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 28.53M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff Research and Development Asset Acquired Other than Through Business Combination, Written-off USD 66.33M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 117.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Research and Development Expense (Excluding Acquired in Process Cost) USD 158.68M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap RestrictedCash Restricted Cash USD 466,000 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 1.59M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.25 2023-11-01 2023-11-30 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap RestructuringCharges Restructuring Charges USD 5.52M 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.73B 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap RevenueFromRelatedParties Revenue from Related Parties USD 0 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-04 0001628280-23-015765
us-gaap Revenues Revenues USD 9,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap SaleAndLeasebackTransactionGainLossNet Sale and Leaseback Transaction, Gain (Loss), Net USD 1.55M 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 13.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.857 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.041 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 4.70M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 1.66M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 52.51 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 100,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 403,651 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 36.96 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 864,491 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 16.93 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 17.09M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 2.70M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 40.32 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value USD 280.84M 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 432.92M 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period shares 975,000 2021-04-01 2021-06-30 2021 Q2 10-Q 2021-08-12 0000950170-21-001389
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 11.07 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 14.25 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 192.72M 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.05 2025-05-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Stock Issued During Period, Shares, Conversion of Convertible Securities shares 194.47M 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-08-12 0000950170-21-001389
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 543,000 2023-04-01 2023-06-30 2024 Q2 10-Q 2024-08-07 0001628280-24-035617
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 3,750 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 33.97M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 1.01B 2021-01-01 2021-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 522,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 1.70M 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-06 0001628280-26-031284
us-gaap StockIssuedDuringPeriodValuePurchaseOfAssets Stock Issued During Period, Value, Purchase of Assets USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 1,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture USD 62.20M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-29 0001628280-22-007708
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 67,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares shares 2.03M 2020-03-01 2020-03-31 2021 Q2 10-Q 2021-08-12 0000950170-21-001389
us-gaap StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value USD 11.81M 2020-01-01 2020-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap SubleaseIncome Sublease Income USD 4.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 0 2021-12-31 2023 FY 10-K 2024-02-28 0001628280-24-007592
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2021-12-31 2021 FY 10-K 2022-03-29 0001628280-22-007708
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 0 2021-12-31 2021 FY 10-K 2022-03-29 0001628280-22-007708
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2021-12-31 2021 FY 10-K 2022-03-29 0001628280-22-007708
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap TransferToInvestments Transfer to Investments USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-02-28 0001628280-23-005572
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 3.46M 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 202,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 1.63M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 69.51M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001628280-26-017253
us-gaap VariableInterestEntityEntityMaximumLossExposureAmount Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount USD 0 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap VariableLeaseCost Variable Lease, Cost USD 4.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 23.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 100,603 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0000950170-21-004270
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 23.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-04 0001628280-26-070171

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →